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ment recommendation by performing the Pearson’s Chi-squared test, Kolmogorov-
Smirnov test, and Wilcoxon rank sum test. Results: In total, 53 pharmacoeconomic 
evaluations were included in this study. Of these, 16 concerned orphan drugs, while 
37 evaluated high cost- drugs. Of the 53 pharmaceutical compounds evaluated in 
this study, 39 (73.6%) received a positive reimbursement advice, 11 (20.8%) received 
a negative reimbursement advice, and 3 drugs were not assessed for reimburse-
ment through either the outpatient reimbursement system nor the intramural 
high cost reimbursement system (5.7%). In total, 277 deviations from the phar-
macoeconomic guidelines were observed, but no single item was found to have a 
statistically significant effect on the reimbursement recommendation. In contrast 
to drug safety and cost-effectiveness outcomes, both drug efficacy and therapeutic 
value showed to have statistically significant impact on the reimbursement deci-
sion. ConClusions: In The Netherlands, drug efficacy and therapeutic value can 
be considered as essential criteria in the reimbursement decision of orphan and 
expensive pharmaceuticals, resulting in a reimbursement system being centered 
on clinical value. Even though cost-effectiveness does not have a significant impact 
on the decision, compliance in the reimbursement dossiers by manufacturers to 
the Dutch Guidelines for Pharmacoeconomic research can be further improved.
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objeCtives: The diagnosis-related group (DRG) based reimbursement system has 
been voluntarily applied to inpatients with seven diseases in the Korean national 
health insurance since 2002, and was mandatory for all health-care institutions 
from July 1, 2013. The main purpose of this study was to evaluate the perfor-
mance of DRG-based reimbursement in health care expenditure and to propose 
alternative policies. Methods: A non-equivalent control group pretest-posttest 
design with a difference-in-difference approach was adopted to compare changes 
in medical service utilization and physician’s behavior between DRG-based 
reimbursement(experimental group) and fee-for-service reimbursement(control 
group). Seven diseases to which DRG-based reimbursement was applied included 
tonsillectomy, cataract surgery, appendectomy, herniotomy, hemorrhoidectomy, 
hysterectomy, and Caesarean section. The panel data were produced from year 
2004~2011 medical claims database of the National Health Insurance, which covered 
a total of 1,119,028 cases per year. Results: From 2004 to 2011, surgical operations 
in institution reimbursed by DRG have been significantly increased more than those 
in institutions reimbursed by fee-for-service. The results showed that the DRG-based 
payment has reduced the length of stay in seven diseases, while it has changed phy-
sician’s behavior to charge DRG-code upward and shift medical tests and expensive 
antibiotics from inpatients to outpatients because DRG was applied to inpatient 
only. The DRG-based payment in seven diseases has consistently increased medi-
cal expenditure as well as medication expenses more than fee-for-service, partly 
due to no global budget in the Korean national health insurance. ConClusions: 
Challenges and future issues to expand the DRG-based reimbursement system to 
all diseases for inpatients should be considered such as monitoring service quality, 
strategic plans to control physicians’ behavior, limiting the number of DRG clas-
sifications, and the introduction of global budgeting.
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objeCtives: Beginning in 2014, the Affordable Care Act requires new health 
plans to cover essential health benefits (EHB), including pharmaceutical products, 
according to the state level benchmark plans. The objectives of this analysis were 
to understand state level variations in design of plans, access to drugs and likely 
impact on patient choice and health outcomes. Methods: Benchmark plans for 
the top five states (i.e., FL, IL, NY, TX and CA), covering ~116 million lives, were 
obtained from the CMS. For each plan, the categories, classes and number of cov-
ered drugs was collected and pooled into one database. Analysis was conducted at 
the entire population level, state-level and for top classes of drugs. The comments 
from patient groups were reviewed to understand the impact of EHB on patient 
choice and health outcomes. Results: Benchmark plans for the top five states 
provide coverage of 4215 drugs belonging to 158 classes as defined by USP. While 
four states (FL, IL, NY and TX) had a similar number of covered drugs (median of 
892 drugs), CA had a significantly lower number of covered drugs, amounting to 
28% less than the other four states. On average, 10% of the drugs were in the class 
called “No USP Class”, highlighting the limitation of CMS designated USP clas-
sification system for the new plans. In CA, FL, IL, NY and TX there were 18, 7, 8, 11 
and 8 classes, respectively, for which only 1 was covered. In CA, top 8 classes were 
identified for which patients had a 75% lower choice than other states, and these 
included indications such as Anti-Diabetics and Pain medications. ConClusions: 
Review of new benchmark plans shows some states can have a significantly lower 
patient choice of therapies. There is a need for new policy measures to ensure that 
all patients have equal access to new treatments.
PHP188
a simulation analysis using tHe orange Price reference tool
Zah V1, Stoykova B2, Walzer S3, Thompson S4
1ZRx Outcomes Research, Mississauga, ON, Canada, 2Daiichi Sankyo, Gerrards Cross, UK, 3MArS 
Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany, 4ZRx Outcomes Research, 
Berlin, Germany
objeCtives: International Reference Pricing (IRP) is a key cost-containment tool 
for health care payers across the world. IRP may apply either fixed or flexible 
determine any trends and drivers of local decision-making. Results: As expected, 
there was variation across CCGs in funding decisions. However, there was only a 
limited correlation between funding decisions and CCG priorities or performance. 
It became evident that there were no strong discernible trends or drivers for local 
funding decisions on these products. ConClusions: Unlike the national level 
assessments undertaken by NICE, the drivers of local formulary decisions on new 
pharmacotherapies are difficult to establish and vary across CCG, making it dif-
ficult for pharmaceutical companies to obtain access for their medicines using a 
“one size fits all” approach. Thus, pharmaceutical companies need to engage more 
closely with CCGs to better understand their needs (including beyond-the-pill) and 
demonstrate the ‘localised’ value of pharmacotherapies.
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objeCtives: Since the introduction of the AMNOG in January 2011, an early benefit 
assessment by the German G-BA is required for all new drugs in Germany. Objective 
of our study was to identify any predictors of G-BA decisions. Methods: All G-BA 
decisions up to 04/2015 were analyzed; basic characteristics of each drug as well as 
of each decision were documented. A multivariate ordinal regression analysis, using 
given additional benefit classification (ranging from 1 for major additional benefit 
to 5 for no additional benefit) as dependent variable, was conducted. Results: 130 
completed G-BA assessment procedures were evaluated. Within these, G-BA deci-
sions were as follows: 16.9% of the drugs received considerable additional benefit 
(for at least one patient subgroup), 23.1% received a minor additional benefit, 10.0% 
received a non-quantifiable additional benefit, and 50.0% received no additional 
benefit. Due to the specifics of German value assessment, orphan drugs auto-
matically receive an additional benefit, but 39.1% of the assessed drugs received a 
non-quantifiable additional benefit (lowest possible assessment). Our multivariate 
regression analysis showed that the strongest predictors for an above-average ben-
efit ranking were proven advantages in mortality (p< 0.001) or morbidity (p= 0.001). 
Additionally, products for use in malignant (p= 0.013) or infectious diseases (p< 0.001) 
as well as orphan treatments (p= 0.027) were more likely to reach a better benefit 
rating. Furthermore, any evidence of a favorable safety profile of a treatment is 
associated with a better ranking (p= 0.10). ConClusions: Key factors for positive 
G-BA decisions seem to be a proven superiority in mortality or morbidity against 
the standard treatment as defined by the German G-BA. However, this is difficult 
to prove in specific chronic disease areas, especially if surrogate outcomes are not 
widely accepted. This may explain why, for example, 80% of the assessed diabetes 
drugs did not receive any additional benefit in Germany.
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objeCtives: In Germany, the reimbursement and pricing of innovative in-patient 
drugs and devices is managed through the NUB application process. These applica-
tions are submitted by the hospital stakeholder and are approved or rejected by the 
Institute for the Hospital Remuneration System (InEK ). The objective of this research 
was to assess the NUB trends in Germany in 2012-2014. Methods: We developed 
a database of NUB approvals and rejections based on the Institute for the Hospital 
Remuneration System’s (InEK )’s reports. All information was extracted into Excel 
format. The following data was extracted: product name, indication, year of submis-
sion, number of NUB applications submitted, status score, type of evidence available 
and lack of evidence for NUB rejection. Additionally, the number of re-applications 
and re-rejections were also analyzed. Results: In 2013 and 2014, a total of 21264 
and 25634 NUB applications were submitted for 612 and 613 medical products, 
respectively. Of these applications in 2013 and 2014, 10% and 16% were approved 
for NUB (as Status 1) and 82% and 75% were rejected (as Status 2), respectively. In 
2014, the median number of hospital applications for NUBs with Status 1 and Status 
2 were 37 and 3, demonstrating the importance of hospital participation for seek-
ing NUB approval. Among approved NUBs, 37% of the applications were for drugs 
and 63% were for devices. Interestingly, the median NUB hospital applications for 
approved drugs was 192, while for devices, the median was 9 applications. In 2014, 
447 NUB applications for products were re-submitted, of which 5 were approved and 
the remaining were re-rejected. The evidence requirements analysis suggests the 
need for hospital focused economic data. ConClusions: The NUB process plays 
a critical role in market access for in-patient drugs and devices. For approval, two 
key components are: hospital focused economic evidence and provider stakeholder 
involvement.
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objeCtives: The aim of this study is to (i) review the methodological quality of 
pharmacoeconomic evaluations of orphan and expensive drugs that applied for 
reimbursement in The Netherlands, and (ii) explore essential criteria in the reim-
bursement recommendations made by The Dutch National Healthcare Institute 
(ZINL). Methods: Data were extracted from pharmacoeconomic reports published 
by ZINL between 1 January 2006 and 31 December 2013 using a data extraction 
form. Compliance to pharmacoeconomic guidelines was determined by evaluat-
ing deviations in the pharmacoeconomic reports from the list of provided items in 
the guidelines. Multiple variables (i.e. drug safety, efficacy, therapeutic value, and 
cost-effectiveness) were investigated regarding their influence on the reimburse-
